AU2007275658B2 - Compositions and methods for the treatment of mucositis - Google Patents

Compositions and methods for the treatment of mucositis Download PDF

Info

Publication number
AU2007275658B2
AU2007275658B2 AU2007275658A AU2007275658A AU2007275658B2 AU 2007275658 B2 AU2007275658 B2 AU 2007275658B2 AU 2007275658 A AU2007275658 A AU 2007275658A AU 2007275658 A AU2007275658 A AU 2007275658A AU 2007275658 B2 AU2007275658 B2 AU 2007275658B2
Authority
AU
Australia
Prior art keywords
compound
formula
alkyl
mucositis
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007275658A
Other languages
English (en)
Other versions
AU2007275658A1 (en
Inventor
Per Gjorstrup
C. Eric Schwartz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resolvyx Pharmaceuticals Inc
Original Assignee
Resolvyx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resolvyx Pharmaceuticals Inc filed Critical Resolvyx Pharmaceuticals Inc
Publication of AU2007275658A1 publication Critical patent/AU2007275658A1/en
Application granted granted Critical
Publication of AU2007275658B2 publication Critical patent/AU2007275658B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007275658A 2006-07-19 2007-07-19 Compositions and methods for the treatment of mucositis Ceased AU2007275658B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83186606P 2006-07-19 2006-07-19
US60/831,866 2006-07-19
PCT/US2007/016338 WO2008011085A1 (en) 2006-07-19 2007-07-19 Compositions and methods for the treatment of mucositis

Publications (2)

Publication Number Publication Date
AU2007275658A1 AU2007275658A1 (en) 2008-01-24
AU2007275658B2 true AU2007275658B2 (en) 2011-09-01

Family

ID=38617335

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007275658A Ceased AU2007275658B2 (en) 2006-07-19 2007-07-19 Compositions and methods for the treatment of mucositis

Country Status (14)

Country Link
US (1) US20100035989A1 (enExample)
EP (1) EP2049099A1 (enExample)
JP (1) JP2009545527A (enExample)
KR (1) KR20090040323A (enExample)
CN (1) CN101528218A (enExample)
AU (1) AU2007275658B2 (enExample)
BR (1) BRPI0714562A2 (enExample)
CA (1) CA2658361C (enExample)
IL (1) IL196465A0 (enExample)
MX (1) MX2009000657A (enExample)
RU (1) RU2009101324A (enExample)
SG (1) SG173397A1 (enExample)
WO (1) WO2008011085A1 (enExample)
ZA (1) ZA200900388B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL151299A0 (en) 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
US8481772B2 (en) * 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7902257B2 (en) * 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US20100190735A1 (en) * 2006-03-28 2010-07-29 Myrex Pharmaceuticals Inc. Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
EP2679224A1 (en) 2007-08-01 2014-01-01 University of Pittsburgh of the Commonwealth System of Higher Education Nitro oleic acid modulation of type II diabetes
CN103191129A (zh) * 2007-10-12 2013-07-10 C.T.辨析有限公司 治疗眼睛病症的脂氧化物类化合物
DK2280928T3 (en) 2008-05-01 2018-11-05 Complexa Inc Vinyl-substituted fatty acids
CN102099024B (zh) 2008-06-19 2015-11-25 犹他大学研究基金会 硝化脂质在毒性医疗疗法的副作用的治疗上的用途
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
US20120122816A1 (en) * 2009-02-05 2012-05-17 Resolvyx Pharmaceuticals, Inc. Compositions and methods for organ preservation
EP2415748A4 (en) 2009-02-20 2013-08-07 Univ Tokyo NEW INFLAMMATORY COMPOUNDS
CA2769624C (en) * 2009-07-31 2018-09-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Electrophilic fatty acid derivatives as anti-inflammatory agents
WO2011041639A2 (en) 2009-10-02 2011-04-07 Miller Raymond A Heteroatom containing substituted fatty acids
EP2744491B1 (en) 2011-08-19 2020-07-29 The University of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
WO2013116753A1 (en) * 2012-02-03 2013-08-08 University Of Pittsburgh-Of The Commonwelth System Of Higher Education Fatty acids as anti-inflammatory agents
CN103417471A (zh) * 2012-05-22 2013-12-04 吴升华 一种治疗湿疹等皮肤炎症的脂氧素乳膏
CA2921845C (en) 2013-08-19 2018-07-10 Korea Research Institute Of Bioscience And Biotechnology Compositions containing monoacetyldiacylglycerol compound as an active indredient for preventing or treating rheumatoid arthritis
CN106163511A (zh) * 2014-01-24 2016-11-23 国立大学法人京都大学 含有稀有脂肪酸的抗炎剂
WO2015176012A1 (en) 2014-05-15 2015-11-19 Enzychem Lifesciences Corporation Methods for treating leukopenia and thrombocytopenia
CA2990521C (en) 2015-07-07 2023-10-10 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
CN113440506A (zh) 2015-10-02 2021-09-28 康普莱克夏公司 使用治疗有效量的活化脂肪酸预防、治疗和逆转疾病
US9808438B2 (en) * 2015-11-09 2017-11-07 Enzychem Lifesciences Corporation Method for treating mucositis
BR112020024019A2 (pt) 2018-05-25 2021-02-23 Imara Inc. monoidrato e formas cristalinas de 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran-4-il-7h-imidazo[1,5-a]pirazin-8-ona
KR20250108770A (ko) 2018-08-31 2025-07-15 카듀리온 파마슈티칼스, 인크. 겸상 세포 질환의 치료를 위한 pde9 억제제

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060778A2 (en) * 2000-02-16 2001-08-23 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US20030191184A1 (en) * 2001-12-18 2003-10-09 Serhan Charles N. Novel approach to anti-microbial host defense with molecular shields with EPA and DHA analogs
WO2003105776A2 (en) * 2002-06-17 2003-12-24 Resolvyx Pharmaceuticals ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
US20030236423A1 (en) * 2002-04-01 2003-12-25 Petasis Nicos A. Trihydroxy polyunsaturated eicosanoids
WO2004014835A2 (en) * 2002-08-12 2004-02-19 Brigham And Women's Hospital Resolvins: biotemplates for therapeutic interventions
US20050113443A1 (en) * 2003-06-01 2005-05-26 Karp Christopher L. Modulation of airway inflammation in patients with cystic fibrosis and related diseases
US20050228047A1 (en) * 2002-04-01 2005-10-13 Petasis Nicos A Trihydroxy polyunsaturated eicosanoid derivatives
WO2006055965A2 (en) * 2004-11-19 2006-05-26 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
AU2006206801A1 (en) * 2005-01-07 2006-07-27 The Brigham And Women's Hospital, Inc. Use of resolvins to treat gastrointestinal diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4576758A (en) * 1984-06-01 1986-03-18 The Upjohn Company Anti-inflammatory lipoxin B analogs
US6887901B1 (en) * 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
JP4392473B2 (ja) * 1999-03-18 2010-01-06 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ホスホリパーゼｄの活性の調節
EP1268393A2 (en) * 2000-03-20 2003-01-02 Trustees Of Boston University Lipoxin analogs and methods for the treatment of periodontal disease
EP1406698B1 (en) * 2001-03-02 2008-10-29 The Brigham and Women's Hospital Lipoxin analogs as novel inhibitors of angiogenesis
EP1453819A2 (en) * 2001-12-03 2004-09-08 Novozymes A/S Statin-like compounds
CA2467580C (en) * 2001-12-18 2012-10-30 Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
US20050203184A1 (en) * 2003-09-10 2005-09-15 Petasis Nicos A. Benzo lipoxin analogues

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060778A2 (en) * 2000-02-16 2001-08-23 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US20030191184A1 (en) * 2001-12-18 2003-10-09 Serhan Charles N. Novel approach to anti-microbial host defense with molecular shields with EPA and DHA analogs
US20030236423A1 (en) * 2002-04-01 2003-12-25 Petasis Nicos A. Trihydroxy polyunsaturated eicosanoids
US20050228047A1 (en) * 2002-04-01 2005-10-13 Petasis Nicos A Trihydroxy polyunsaturated eicosanoid derivatives
WO2003105776A2 (en) * 2002-06-17 2003-12-24 Resolvyx Pharmaceuticals ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
WO2004014835A2 (en) * 2002-08-12 2004-02-19 Brigham And Women's Hospital Resolvins: biotemplates for therapeutic interventions
US20050113443A1 (en) * 2003-06-01 2005-05-26 Karp Christopher L. Modulation of airway inflammation in patients with cystic fibrosis and related diseases
WO2006055965A2 (en) * 2004-11-19 2006-05-26 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
AU2006206801A1 (en) * 2005-01-07 2006-07-27 The Brigham And Women's Hospital, Inc. Use of resolvins to treat gastrointestinal diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PNAS, 2005, 102(21): 7671-7676 *

Also Published As

Publication number Publication date
IL196465A0 (en) 2009-11-18
AU2007275658A1 (en) 2008-01-24
JP2009545527A (ja) 2009-12-24
CA2658361C (en) 2013-04-23
CA2658361A1 (en) 2008-01-24
CN101528218A (zh) 2009-09-09
KR20090040323A (ko) 2009-04-23
WO2008011085A1 (en) 2008-01-24
EP2049099A1 (en) 2009-04-22
BRPI0714562A2 (pt) 2013-04-02
ZA200900388B (en) 2010-03-31
RU2009101324A (ru) 2010-07-27
US20100035989A1 (en) 2010-02-11
MX2009000657A (es) 2009-05-28
SG173397A1 (en) 2011-08-29

Similar Documents

Publication Publication Date Title
CA2658361C (en) Ophthalmic formulations for the treatment of inflammation
RU2669800C2 (ru) Способы лечения воспаления, аутоиммунных расстройств и боли
EP2207543A2 (en) Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for treating autoimmune diseases or inhibiting immune function
PL209943B1 (pl) Zastosowanie moksifloksacyny stanowiącej kwas 1-cyklopropylo-6-fluoro-1,4-dihydro-8-metoksy-7-[(4aS,7aS)-oktahydro-6H-pirolo [3,4-b]pirydyn-6-ylo]-4-okso-3-chinolino-karboksylowy
JPH11506421A (ja) 腸感染に対する薬物の調製のためのフマギロールおよびその誘導体の使用
JPH10503200A (ja) 抗カビ性創傷治癒組成物およびその調製および使用のための方法
WO2008070129A2 (en) Compositions and methods for the treatment of inflammatory disease
EP0828515A1 (en) Antibacterial-wound healing compositions and methods for preparing and using same
JP2001517213A (ja) Ｈｅｌｉｃｏｂａｃｔｅｒ種による感染症の予防および治療用経口製剤
DE60140491D1 (de) Verwendung einer pharmazeutischen Zusammensetzung mit einem Para-Aminophenylessigsäurederivat für die Behandlung von entzündlichen Erkrankungen des Magen-Darmtrakts
EP2393353A1 (en) Compositions and methods for organ preservation
BRPI0707008A2 (pt) associação em doses fixas de fitato e zinco
WO2011109472A1 (en) Compositions comprising myristic acid and uses thereof
US20080161274A1 (en) Compounds and methods for inhibition of bone loss
KR940703840A (ko) 치환 벤즈이미다졸, 그의 제조 방법 및 용도(substituted benzimidazoles, process for their preparation as well as their use)
WO2004075906A1 (ja) 抗炎症剤及び抗炎症性医療材料
US20120178787A1 (en) Melatonin and its use in preventing postoperative complications
US4446149A (en) Medicine for treatment of cervical erosion
AU2016340017A1 (en) Compositions and methods for the treatment of diseases involving mucin
US20100305144A1 (en) Prevention of recurrence of urethral stricture after a conventional treatment
US9388155B1 (en) Coumarin derivatives for cancer therapy
MXPA05002062A (es) Modulacion de la actividad de la metaloproteinasa de la matriz con bloqueador(es) de aldosterona.
JP2018090540A (ja) 歯槽骨吸収抑制剤
AU711789B2 (en) Antibacterial-wound healing compositions and methods for preparing and using same
TW200407118A (en) Inhibitor of anticancer drug side effect

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 19 JUL 2012 TO 19 MAR 2013 IN WHICH TO PAY A RENEWAL FEE HAS BEEN FILED .

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 19 MAR 2013.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired